Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence.
The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence in women. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence. This is a randomized prospective controlled study of two active groups with a stimulation frequency difference between the groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Group A | Experimental | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A. |
|
| Active Group B | Active Comparator | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ELITONE UUI | Device | External electrical stimulation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Average Number of Urinary Incontinence Episodes Per Day | The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period. | 6 weeks |
| Safety Assessed by Number of Serious Adverse Events | Any serious adverse events recorded during the trial. | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL) | The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110. |
Not provided
Inclusion Criteria:
Predominant urge urinary incontinence as determined by responses to a series of three standard questions from the King's Health Questionnaire; specifically:
Mild-moderate incontinence symptoms as determined by self-reported typical number of accidents of 1 or more per 24 hours. Symptom severity is later verified with data from the Daily Log (See 5.4)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gloria Kolb, M.S. | Elidah, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Elidah | Monroe | Connecticut | 06468 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Active Group A | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A (urge only for 6 seconds/cycle). ELITONE UUI: External electrical stimulation |
| FG001 | Active Group B | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B (urge and stress) ELITONE UUI: External electrical stimulation |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Active Group A | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A (urge only for 6 seconds/cycle). ELITONE UUI: External electrical stimulation |
| BG001 | Active Group B |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Average Number of Urinary Incontinence Episodes Per Day | The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period. | Total of 82 participants, but only 51 completed the trial. | Posted | Mean | Standard Deviation | percentage change | 6 weeks |
|
6 weeks of study
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Active Group A | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A. ELITONE UUI: External electrical stimulation |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Clinical Trials | Elidah, Inc. | 978.435.4324 | customercare@elitone.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 8, 2020 | Jan 28, 2022 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D053202 | Urinary Incontinence, Urge |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Randomized between two active groups
Not provided
Not provided
Device looks identical. A third person masks which software is coded.
| 6 weeks |
| Efficacy Assessed by Reduction in Average Pads Used Per Day | Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period. | 6 weeks |
| Efficacy Assessed by Reduction in Average Bathroom Visits | The efficacy assessed by average bathroom visits during the day and night. | 6 weeks |
Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B (urge and stress) ELITONE UUI: External electrical stimulation |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
|
| Primary | Safety Assessed by Number of Serious Adverse Events | Any serious adverse events recorded during the trial. | There were no adverse events for any participants | Posted | Mean | Standard Deviation | serious adverse events | 6 weeks |
|
|
|
| Secondary | Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL) | The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110. | Posted | Mean | Standard Deviation | change of score on a scale | 6 weeks |
|
|
|
| Secondary | Efficacy Assessed by Reduction in Average Pads Used Per Day | Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period. | Posted | Mean | Standard Deviation | percentage of change | 6 weeks |
|
|
|
| Secondary | Efficacy Assessed by Reduction in Average Bathroom Visits | The efficacy assessed by average bathroom visits during the day and night. | Posted | Mean | Standard Deviation | percentage of change | 6 weeks |
|
|
|
| 0 |
| 17 |
| 0 |
| 17 |
| 0 |
| 17 |
| EG001 | Active Group B | Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B. ELITONE UUI: External electrical stimulation | 0 | 34 | 0 | 34 | 0 | 34 |
Not provided
Not provided
Not provided
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |